Back to results
US 2024/0181072 A1Published application
Anti-HER2 Antibody-Immune Agonist Conjugate and Applications Thereof
AssigneesGenequantum Healthcare (Suzhou) Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd.
InventorsPaul H. SONG, Gang QIN, Jiandong YUAN, Chong LIU
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a linking unit molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof, and in particular relates to an anti-HER2 antibody-immune agonist conjugate (AIAC) as a novel type of cancer therapy.
Claims9
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An antibody-drug conjugate, which is selected from the following structures:
- z is an integer of 1 to 4;
- A is an antibody comprising a light chain having the amino acid sequence of SEQ ID NO:
- 1 and a heavy chain having the amino acid sequence of SEQ ID NO:
- 2.
1 more element
Dependencies are inferred from the claim text.